|
시장보고서
상품코드
2050452
GLP-1 수용체 작용제 시장 : 약제 유형별, 브랜드별, 용도별, 투여 경로별, 유형별, 성별, 연령층별, 유통 채널별, 지역별Glucagon Like Peptide 1 Analogs Market, By Drug Type,, By Brand,, By Application,, By Route of Administration, By Type, By Gender, By Age Group, By Distribution Channel, By Geography |
||||||
GLP-1 수용체 작용제 시장은 2026년에 590억 1,000만 달러로 추계되고 있으며, 2033년까지 1,172억 1,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 10.3%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 5,910억 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 10.30% | 2033년 시장 규모 예측 : | 1,172억 1,000만 달러 |
GLP-1 수용체 작용제 시장은 당뇨병 치료 분야에서 혁신적인 분야로, 제2형 당뇨병 및 비만 관리의 치료 패러다임을 근본적으로 변화시키고 있습니다. GLP-1 유사체는 자연적으로 존재하는 인크레틴 호르몬인 GLP-1의 합성 버전으로, 인슐린 분비 촉진, 글루카곤 방출 억제, 위 내용물 배출 지연을 통해 혈당 항상성 유지에 중요한 역할을 합니다. 이러한 혁신적인 치료제는 혈당 조절과 체중 감소라는 이중 작용 기전을 통해 혈당 조절과 체중 감소라는 두 가지 이점을 모두 제공하는 치료의 기본 치료법으로 부상하고 있습니다.
이 시장에는 1일 1회 투여, 주 1회 투여, 그리고 새롭게 등장한 장기지속형 제제 등 다양한 제제가 포함되어 있으며, 환자의 다양한 선호도와 치료 프로토콜에 대응하고 있습니다. 주요 기업은 첨단 전달 시스템을 통해 약물의 효능을 높이고, 부작용을 줄이며, 환자의 복약 순응도를 높이기 위해 연구개발에 많은 투자를 해왔습니다. 전 세계에서 당뇨병 유병률이 증가하고 비만과 관련된 동반 질환에 대한 인식이 높아짐에 따라 GLP-1 유사체는 의료진들 사이에서 선호되는 치료 옵션으로 자리매김하고 있습니다. 이 시장 부문은 심혈관 위험 감소 및 잠재적인 신경 보호 효과 등 임상 적용 범위의 확대에 힘입어 꾸준히 성장하고 있으며, 현대 제약 산업에서 가장 역동적이고 빠르게 진화하는 분야 중 하나입니다.
시장 역학
GLP-1 수용체 작용제 시장은 견고한 성장 궤도를 지원하는 몇 가지 강력한 촉진요인에 의해 주도되고 있습니다. 주요 촉진요인은 전 세계에서 5억 3,700만 명 이상의 성인이 당뇨병을 앓고 있으며, 전 세계에서 제 2형 당뇨병과 비만 유병률이 급증하고 있으며, 효과적인 치료법에 대한 전례 없는 수요가 발생하고 있다는 점입니다. GLP-1 유사체는 현저한 HbA1c 감소와 함께 체중감소 효과를 보이는 우수한 유효성 프로파일을 가지고 있으며, 기존 당뇨병 치료제에 비해 선호되는 치료 옵션으로 자리매김하고 있습니다. 또한 심혈관 보호 효과와 비알코올성 지방간 질환(NAFLD)에 대한 잠재적 적용 가능성을 지원하는 임상적 근거가 확대되면서 치료의 적용 범위가 넓어지고 시장 확산이 촉진되고 있습니다. 서방형 제제, 혁신적인 주사 장치 등 약물전달 시스템의 기술 발전은 환자의 편의성과 복약 순응도를 향상시켜 시장 성장을 더욱 촉진하고 있습니다. 그러나 시장에는 눈에 띄는 제약도 존재합니다. 주요 요인은 기존 당뇨병 치료제 대비 GLP-1 유사체의 높은 비용으로, 특히 가격에 민감한 시장에서는 접근의 장벽이 되고 특정 지역에서는 보험 적용이 제한되는 요인으로 작용하고 있습니다.
메스꺼움, 구토, 설사 등 위장관계 부작용은 환자의 복약 순응도 및 치료 지속에 영향을 미쳐 시장 침투를 저해할 수 있습니다. 펩티드 계열 생물제제의 제조상의 복잡성은 공급망상의 어려움과 비용 측면의 영향을 가져옵니다. 그럼에도 불구하고 당뇨병 유병률이 빠르게 증가하고 있는 개발도상국의 미개발 시장에서는 의료 인프라 개선 및 보험 적용 범위 확대와 함께 큰 기회가 창출되고 있습니다. GLP-1 유사체와 다른 당뇨병 치료제를 결합한 병용요법의 가능성은 수익성 높은 개발 기회를 제공합니다. 또한 알츠하이머병, 파킨슨병, 기타 대사성 질환을 포함한 새로운 적응증에 대한 연구가 진행 중이며, 이는 대상 시장을 크게 확대하여 GLP-1 유사체는 당뇨병 관리를 넘어 다용도한 치료 플랫폼으로 자리매김할 수 있을 것으로 기대됩니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 매출기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택한 경쟁 전략에 대한 중요 인사이트를 제공합니다.
- 이 보고서에서는 글로벌 글루카곤 유사 펩티드-1(GLP-1) 아날로그 시장의 주요 기업 개요을 회사 개요, 제품 포트폴리오, 주요 특징, 재무 실적, 전략 등의 정보를 바탕으로 정리하여 전해드립니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 이 세계의 글루카곤 유사 펩티드 1 유사체 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가를 포함한 업계의 다양한 이해관계자를 대상으로 합니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 GLP-1 수용체 작용제 시장 : 약제 유형별, 2021-2033년
제5장 GLP-1 수용체 작용제 시장 : 브랜드별, 2021-2033년
제6장 GLP-1 수용체 작용제 시장 : 용도별, 2021-2033년
제7장 GLP-1 수용체 작용제 시장 : 투여 경로별, 2021-2033년
제8장 GLP-1 수용체 작용제 시장 : 유형별, 2021-2033년
제9장 GLP-1 수용체 작용제 시장 : 성별, 2021-2033년
제10장 GLP-1 수용체 작용제 시장 : 연령층별, 2021-2033년
제11장 GLP-1 수용체 작용제 시장 : 유통 채널별, 2021-2033년
제12장 세계의 GLP-1 수용체 작용제 시장 : 지역별, 2021-2033년
제13장 경쟁 구도
제14장 애널리스트의 제안
제15장 참고 문헌 및 조사 방법
KSA 26.06.09Glucagon Like Peptide 1 Analogs Market is estimated to be valued at USD 59.01 Bn in 2026 and is expected to reach USD 117.21 Bn by 2033, growing at a compound annual growth rate (CAGR) of 10.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 59.01 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 10.30% | 2033 Value Projection: | USD 117.21 Bn |
The glucagon like peptide 1 analogs market represents a revolutionary segment within the diabetes therapeutics landscape, fundamentally transforming treatment paradigms for Type 2 diabetes mellitus and obesity management. GLP-1 analogs are synthetic versions of the naturally occurring incretin hormone GLP-1, which plays a crucial role in glucose homeostasis by stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying. These innovative therapeutic agents have emerged as cornerstone treatments due to their dual mechanism of action, offering both glycemic control and significant weight reduction benefits.
The market encompasses various formulations including once-daily, once-weekly, and emerging longer-acting preparations, catering to diverse patient preferences and treatment protocols. Leading pharmaceutical companies have invested heavily in research and development to enhance drug efficacy, reduce side effects, and improve patient compliance through advanced delivery systems. The growing prevalence of diabetes worldwide, coupled with increasing awareness of obesity-related comorbidities, has positioned GLP-1 analogs as preferred therapeutic options among healthcare providers. This market segment continues to witness robust growth driven by expanding clinical applications, including cardiovascular risk reduction and potential neuroprotective effects, making it one of the most dynamic and rapidly evolving sectors in modern pharmaceutical industry.
Market Dynamics
The glucagon like peptide 1 analogs market is propelled by several compelling drivers that underscore its robust growth trajectory. The primary driver is the escalating global prevalence of Type 2 diabetes and obesity, with over 537 million adults currently living with diabetes worldwide, creating an unprecedented demand for effective therapeutic interventions. The superior efficacy profile of GLP-1 analogs, demonstrating significant HbA1c reduction alongside substantial weight loss benefits, positions these agents as preferred treatment options over traditional diabetes medications. Additionally, expanding clinical evidence supporting cardiovascular protective effects and potential applications in non-alcoholic fatty liver disease (NAFLD) broadens the therapeutic scope, driving market adoption. Technological advancements in drug delivery systems, including extended-release formulations and innovative injection devices, enhance patient convenience and adherence, further stimulating market growth. However, the market faces notable restraints, primarily the high cost of GLP-1 analogs compared to conventional diabetes treatments, creating accessibility barriers particularly in price-sensitive markets and limiting insurance coverage in certain regions.
Gastrointestinal side effects, including nausea, vomiting, and diarrhea, can impact patient compliance and treatment continuation, potentially hindering market penetration. Manufacturing complexities associated with peptide-based biologics pose supply chain challenges and cost implications. Nevertheless, significant opportunities emerge from untapped markets in developing economies where diabetes prevalence is rapidly increasing, coupled with improving healthcare infrastructure and expanding insurance coverage. The potential for combination therapies integrating GLP-1 analogs with other diabetes medications presents lucrative development opportunities. Furthermore, ongoing research into novel indications including Alzheimer's disease, Parkinson's disease, and other metabolic disorders could substantially expand the addressable market, positioning GLP-1 analogs as versatile therapeutic platforms beyond diabetes management.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global glucagon like peptide 1 analogs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca, Boehringer Ingelheim, Merck & Co., Amgen, GlaxoSmithKline, Bristol-Myers Squibb, Takeda Pharmaceutical Company, Daiichi Sankyo, Pfizer, Teva Pharmaceutical Industries, Regeneron Pharmaceuticals, Intarcia Therapeutics, and Hngzhou Jiuyuan Gene Engineering Co Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global glucagon like peptide 1 analogs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
- Drug Type Insights (Revenue, USD Bn, 2021 - 2033)
- Semaglutide
- Liraglutide
- Exenatide
- Dulaglutide
- Tirzepatide
- Others
- Linagliptin
- Lixisenatide
- Brand Insights (Revenue, USD Bn, 2021 - 2033)
- Saxenda
- Victoza
- Ozempic
- Wegovy
- Rybelsus
- Trulicity Pen
- Zepbound
- Mounjaro
- BYDUREON BCise
- Others
- Application Insights (Revenue, USD Bn, 2021 - 2033)
- Type 2 Diabetes Mellitus
- Weight Management (Obesity/Overweight)
- Cardiovascular Risk Reduction
- Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Parenteral
- Type Insights (Revenue, USD Bn, 2021 - 2033)
- Brand
- Generic
- Gender Insights (Revenue, USD Bn, 2021 - 2033)
- Male
- Female
- Age Group Insights (Revenue, USD Bn, 2021 - 2033)
- Adult
- Pediatric/Children
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Novo Nordisk
- Eli Lilly and Company
- Sanofi
- AstraZeneca
- Boehringer Ingelheim
- Merck & Co.
- Amgen
- GlaxoSmithKline
- Bristol-Myers Squibb
- Takeda Pharmaceutical Company
- Daiichi Sankyo
- Pfizer
- Teva Pharmaceutical Industries
- Regeneron Pharmaceuticals
- Intarcia Therapeutics
- Hngzhou Jiuyuan Gene Engineering Co Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Glucagon Like Peptide 1 Analogs Market, By Drug Type
- Glucagon Like Peptide 1 Analogs Market, By Brand
- Glucagon Like Peptide 1 Analogs Market, By Application
- Glucagon Like Peptide 1 Analogs Market, By Route of Administration
- Glucagon Like Peptide 1 Analogs Market, By Type
- Glucagon Like Peptide 1 Analogs Market, By Gender
- Glucagon Like Peptide 1 Analogs Market, By Age Group
- Glucagon Like Peptide 1 Analogs Market, By Distribution Channel
- Glucagon Like Peptide 1 Analogs Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Glucagon Like Peptide 1 Analogs Market, By Drug Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Semaglutide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Liraglutide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Exenatide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Dulaglutide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Tirzepatide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Linagliptin
- Lixisenatide
5. Glucagon Like Peptide 1 Analogs Market, By Brand, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Saxenda
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Victoza
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Ozempic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Wegovy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Rybelsus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Trulicity Pen
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Zepbound
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Mounjaro
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- BYDUREON BCise
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Glucagon Like Peptide 1 Analogs Market, By Application, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Type 2 Diabetes Mellitus
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Weight Management (Obesity/Overweight)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Cardiovascular Risk Reduction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Glucagon Like Peptide 1 Analogs Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Glucagon Like Peptide 1 Analogs Market, By Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Brand
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Glucagon Like Peptide 1 Analogs Market, By Gender, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Glucagon Like Peptide 1 Analogs Market, By Age Group, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Pediatric/Children
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
11. Glucagon Like Peptide 1 Analogs Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
12. Global Glucagon Like Peptide 1 Analogs Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Brand, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Application, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
13. Competitive Landscape
- Novo Nordisk
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Daiichi Sankyo
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Regeneron Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Intarcia Therapeutics
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hngzhou Jiuyuan Gene Engineering Co Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
14. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
15. References and Research Methodology
- References
- Research Methodology
- About us
